NeoGenomics (NEO)
(Real Time Quote from BATS)
$13.16 USD
-0.26 (-1.94%)
Updated Jun 14, 2024 10:00 AM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
NeoGenomics, Inc. [NEO]
Reports for Purchase
Showing records 61 - 80 ( 132 total )
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Sector Consolidation Bodes Well for NeoGenomics
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Volume Growth Laying the Foundation for Revenue Acceleration
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Preview; Reimbursement Headwinds Obscure Robust Core Business Trends
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Reimbursement Headwinds Could Dissipate Midyear
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/14 Results Positive; 2015E less certain
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Challenging Reimbursement Environment; Market Share Gains
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-announces 4Q14 Beat, Continued Execution In A Challenging Environment
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
FMI''s Deal with Roche Could Have Positive Ramifications.
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: NeoGenomics, Inc.
Industry: Medical - Biomedical and Genetics
Expecting An Inline Q4-2014, but 2015, Could Have an Upside Bias
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D